ARN 077

• Description :

  ARN 077 is a potent and selective N-acylethanolamine acid amidase (NAAA) inhibitor with an IC50 of 7 nM for human NAAA[1]. ARN 077 significantly increases palmitoyl ethanolamine (PEA) levels within the CNS and has broad antinociceptive activity in mice and rats[2].

• CAS Number :

  [1373625-34-3]

• Product Name Alternative :

  URB913

• UNSPSC :

  12352005

• Target :

  Ceramidase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ARN_077.html

• Purity :

  98.83

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  O=C(OCCCCCC1=CC=CC=C1)N[C@@H]2[C@H](C)OC2=O

• Molecular Formula :

  C16H21NO4

• Molecular Weight :

  291.34

• References & Citations :

  [1]Sasso O, et al. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain. 2013 Mar;154 (3) :350-60.|[2]Davis MP, et al. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs. 2014 Aug;23 (8) :1123-40.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported